Patent · US Active

High purity oritavancin and method of producing same

US10864249B2 · kind B2 · utility

0Cited by

5References

21Claims

0Family size

Assignees

MELINTA THERAPEUTICS, INC. · US
Abb Vie Inc. · US

Inventors

Adel Rafai Far · Montréal, CA
Gopal Krishna · Dover, US
Min Ding · Dobbs Ferry, US
Sanjay R. Chemburkar · Gurnee, US
Carl M. Knable · North Chicago, US
James P. Petzel · North Chicago, US
Julie J. Pruyne · Gurnee, US
Douglas M. Reamer · North Chicago, US

Key dates

Filing date	Jun 11, 2019
Grant date	Dec 15, 2020
Priority date	—
Expiry date	Jun 11, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12P21/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.